Literature DB >> 31335387

Introduction by the Guest Editor: Oncologic Precision Medicine and the Use of Basket and Umbrella Clinical Trials.

James H Doroshow1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31335387      PMCID： PMC6669000          DOI： 10.1097/PPO.0000000000000394

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


× No keyword cloud information.
  14 in total

1.  Selecting systemic cancer therapy one patient at a time: is there a role for molecular profiling of individual patients with advanced solid tumors?

Authors:  James H Doroshow
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Application of molecular profiling in clinical trials for advanced metastatic cancers.

Authors:  Shivaani Kummar; P Mickey Williams; Chih-Jian Lih; Eric C Polley; Alice P Chen; Larry V Rubinstein; Yingdong Zhao; Richard M Simon; Barbara A Conley; James H Doroshow
Journal:  J Natl Cancer Inst       Date:  2015-02-06       Impact factor: 13.506

3.  Perspectives on the development of imatinib and the future of cancer research.

Authors:  Brian J Druker
Journal:  Nat Med       Date:  2009-10       Impact factor: 53.440

4.  Limits to Personalized Cancer Medicine.

Authors:  Ian F Tannock; John A Hickman
Journal:  N Engl J Med       Date:  2016-09-29       Impact factor: 91.245

5.  Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both.

Authors:  Janet Woodcock; Lisa M LaVange
Journal:  N Engl J Med       Date:  2017-07-06       Impact factor: 91.245

6.  Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.

Authors:  Apostolia-Maria Tsimberidou; Nancy G Iskander; David S Hong; Jennifer J Wheler; Gerald S Falchook; Siqing Fu; Sarina Piha-Paul; Aung Naing; Filip Janku; Rajyalakshmi Luthra; Yang Ye; Sijin Wen; Donald Berry; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2012-09-10       Impact factor: 12.531

7.  A history of cancer chemotherapy.

Authors:  Vincent T DeVita; Edward Chu
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

Review 8.  Translational research in oncology--10 years of progress and future prospects.

Authors:  James H Doroshow; Shivaani Kummar
Journal:  Nat Rev Clin Oncol       Date:  2014-10-07       Impact factor: 66.675

9.  Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.

Authors:  Eirini Pectasides; Matthew D Stachler; Sarah Derks; Yang Liu; Steven Maron; Adam J Bass; Daniel V Catenacci; Mirazul Islam; Lindsay Alpert; Heewon Kwak; Hedy Kindler; Blase Polite; Manish R Sharma; Kenisha Allen; Emily O'Day; Samantha Lomnicki; Melissa Maranto; Rajani Kanteti; Carrie Fitzpatrick; Christopher Weber; Namrata Setia; Shu-Yuan Xiao; John Hart; Rebecca J Nagy; Kyoung-Mee Kim; Min-Gew Choi; Byung-Hoon Min; Katie S Nason; Lea O'Keefe; Masayuki Watanabe; Hideo Baba; Rick Lanman; Agoston T Agoston; David J Oh; Andrew Dunford; Aaron R Thorner; Matthew D Ducar; Bruce M Wollison; Haley A Coleman; Yuan Ji; Mitchell C Posner; Kevin Roggin; Kiran Turaga; Paul Chang; Kyle Hogarth; Uzma Siddiqui; Andres Gelrud; Gavin Ha; Samuel S Freeman; Justin Rhoades; Sarah Reed; Greg Gydush; Denisse Rotem; Jon Davison; Yu Imamura; Viktor Adalsteinsson; Jeeyun Lee
Journal:  Cancer Discov       Date:  2017-10-04       Impact factor: 39.397

10.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Authors:  Christophe Le Tourneau; Jean-Pierre Delord; Anthony Gonçalves; Céline Gavoille; Coraline Dubot; Nicolas Isambert; Mario Campone; Olivier Trédan; Marie-Ange Massiani; Cécile Mauborgne; Sebastien Armanet; Nicolas Servant; Ivan Bièche; Virginie Bernard; David Gentien; Pascal Jezequel; Valéry Attignon; Sandrine Boyault; Anne Vincent-Salomon; Vincent Servois; Marie-Paule Sablin; Maud Kamal; Xavier Paoletti
Journal:  Lancet Oncol       Date:  2015-09-03       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.